Details

Autor(en) / Beteiligte

• Guy, R Kiplin
• DiPaola, Robert S
• Romanelli, Frank
• Dutch, Rebecca E

Titel

Rapid repurposing of drugs for COVID-19

Ist Teil von

• Science (American Association for the Advancement of Science), 2020-05, Vol.368 (6493), p.829-830

Ort / Verlag

United States: The American Association for the Advancement of Science

Erscheinungsjahr

2020

Quelle

American Association for the Advancement of Science

Beschreibungen/Notizen

• The emergence of a new coronaviral respiratory disease calls for repurposing existing drugs In late fall 2019, a novel acute respiratory disease, called coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. COVID-19 is caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) ( 1 , 2 ). COVID-19 has been declared a pandemic by the World Health Organization and continues to spread across the globe. Most patients recover within 1 to 3 weeks. However, a small proportion (∼5%) develop severe illness that can progress to acute respiratory distress syndrome (ARDS), which can lead to death. Currently, only supportive care is available; patients would greatly benefit from the availability of direct therapeutic approaches. One approach to identifying therapeutics is to repurpose approved drugs developed for other uses, which takes advantage of existing detailed information on human pharmacology and toxicology to enable rapid clinical trials and regulatory review.